Table 1. Clinical Characteristics of Study Participants by Study Stage.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Stage 1 | Stage 2 | Stage 1 and 2 | |
| Total patients | 5545 | 12 001 | 17 546 |
| Aggressive PCa | |||
| Patients | 2770 (50.0) | 6415 (53.5) | 9185 (52.3) |
| Age at diagnosis, mean (SD), y | 66.1 (8.8) | 64.7 (9.3) | 65.1 (9.2) |
| First-degree PCa family history | |||
| Yes | 331 (11.9) | 925 (14.4) | 1256 (13.7) |
| No | 1776 (64.1) | 3080 (48.0) | 4856 (52.9) |
| Missing | 663 (23.9) | 2410 (37.6) | 3073 (33.4) |
| Death due to PCa | |||
| Yes | 2052 (74.1) | 3981 (62.1) | 6033 (65.7) |
| No | 311 (11.2) | 369 (5.8) | 680 (7.4) |
| Missing | 407 (14.7) | 2065 (32.2) | 2472 (26.9) |
| Metastatic disease at diagnosis or follow-up | |||
| Yes | 467 (16.9) | 1930 (30.1) | 2397 (26.1) |
| No | 663 (23.9) | 1849 (28.8) | 2512 (27.3) |
| Missing | 1640 (59.2) | 2636 (41.1) | 4276 (46.6) |
| Category | |||
| T1 | 410 (14.8) | 1045 (16.3) | 1455 (15.8) |
| T2 | 367 (13.2) | 946 (14.7) | 1313 (14.3) |
| T3 | 1277 (46.1) | 2035 (31.7) | 3312 (36.1) |
| T4 | 654 (23.6) | 1449 (22.6) | 2103 (22.9) |
| Missing | 62 (2.2) | 940 (14.7) | 1002 (10.9) |
| Gleason score at diagnosis | |||
| ≤6 | 197 (7.1) | 923 (14.4) | 1120 (12.2) |
| 7 | 490 (17.7) | 1311 (20.4) | 1801 (19.6) |
| 8-10 | 1862 (67.2) | 2794 (43.6) | 4656 (50.7) |
| Missing | 221 (8.0) | 1387 (21.6) | 1608 (17.5) |
| PSA at diagnosis, median (IQR), ng/mL | 30.9 (10.0-105.0) | 18.0 (7.5-66.0) | 20.4 (8.0-77.0) |
| Missing | 661 (23.9) | 1184 (18.5) | 1845 (20.1) |
| Nonaggressive PCa | |||
| Patients | 2775 (50.0) | 5586 (46.5) | 8361 (47.7) |
| Age at diagnosis, mean (SD), y | 67.5 (7.0) | 61.8 (7.7) | 63.7 (8.0) |
| First-degree PCa family history | |||
| Yes | 467 (16.8) | 1003 (18.0) | 1470 (17.6) |
| No | 1816 (65.4) | 2810 (50.3) | 4626 (55.3) |
| Missing | 492 (17.7) | 1773 (31.7) | 2265 (27.1) |
| Category | |||
| T1 | 2383 (85.9) | 4110 (73.6) | 6493 (77.7) |
| T2 | 392 (14.1) | 1476 (26.4) | 1868 (22.3) |
| Gleason Score ≤6 at diagnosis | 2773 (99.9) | 5586 (100) | 8359 (99.9) |
| Missing | 2 (0.07) | 0 (0) | 2 (0.02) |
| PSA at diagnosis, median (IQR), ng/mL | 7.1 (5.0-10.4) | 5.9 (4.3-8.4) | 6.2 (4.4-9.1) |
| Missing | 659 (23.7) | 785 (14.1) | 1444 (17.3) |
| Follow-up years, median (IQR) | 11.4 (10.0-14.0) | 8.5 (4.2-12.0) | 10.0 (6.0-13.0) |
| Missing | 260 (9.4) | 84 (1.5) | 344 (4.1) |
Abbreviations: PCa, prostate cancer; PSA, prostate-specific antigen.